Business
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours
About this update from Kiniksa Pharmaceuticals International, Plc
[{"type":"image","alt":"Kiniksa Pharmaceuticals International, Plc","displaySize":"","headline":null,"caption":"Kiniksa Pharmaceuticals International, Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":207,"url":"https://media.zenfs.com/en/globenewswire.com/84bc4259d2877b369755dfd109eaa0a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wfBd0ZwknGs8QtzbckR3vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/84bc4259d2877b369755dfd109eaa0a5","width":300,"height":207}},"lazy":false},{"type":"text","content":"LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).","length":274,"tagName":"p"},{"type":"text","content":"A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.","length":247,"tagName":"p"},{"type":"text","content":"About KiniksaKiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.","length":478,"tagName":"p"},{"type":"text","content":"Every Second Counts! ®","length":22,"tagName":"p"},{"type":"text","content":"Kiniksa Investor & Media ContactJonathan Kirshenbaum(781) [email protected]","length":97,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]
More updates from Kiniksa Pharmaceuticals International, Plc